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Background
The association between specific HLA alleles and risk of
severe cutaneous drug hypersensitivity reactions is increas-
ingly recognised. Vancomycin mediated pseudo-allergic
‘red man syndrome’ is well recognised, yet urticaria/ana-
phylaxis is uncommon and some clinical reactions are
delayed. Although this may suggest the presence of vanco-
mycin initiated T cell responses, no predisposing vancomy-
cin HLA association has been identified. Therefore we set
out to examine the role of T cell responses in vancomycin
hypersensitivity reactions.
Methods
Of our tested cohort of 103 individuals who suffered
delayed skin drug hypersensitivity reactions, vancomycin
was deemed the culprit in 17, who developed drug
exanthems (59%), DRESS (35%), or SJS/TEN (18%). We
used ELISpot and [3H]-Thymidine assays to measure van-
comycin-specific ex-vivo IFN-/IL-4 and proliferation above
background.
Results
Individuals with drug hypersensitivity showed a mean cir-
culating PBMC frequency of vancomycin-specific cells of
470.0 x10-4% (IFN-) / 33.5 x10-4% (IL-4) and SI 4.08 if
tested within 30 days, whilst those tested after 30 days
showed 316.0 x10-4% (IFN-) / 20.0 x10-4% (IL-4) and SI
3.43. Individuals never previously exposed to vancomycin
(n=11) showed a lower mean circulating frequency: 2.1
x10-4% (IFN-, p<0.005)) / 1.7 x10-4% (IL-4, p=0.27) and SI
1.28. In controls who had been exposed to vancomycin
(without any evidence of a hypersensitivity reaction, n=6)
detectable frequencies were also lower than allergics:
11 x10-4% (IFN-) / 7.1 x10-4% (IL-4) and SI 0.98. We
co-cultured non-allergic PBMC with vancomycin for
two-weeks in vitro. In two lines, we saw expansion of van-
comycin-specific T cells in ELISpot to an average frequency
of 954 x10-4% (IFN-) and 1130 x10-4% (IL-4) which was
confirmed by ELISpot and intracellular cytokine staining.
Conclusion
These data confirm that robust Th1 responses target van-
comycin in cutaneous hypersensitivity reactions, which
supports the use of T cell inhibition such as steroids and
ciclosporin. Vancomycin-specific responses appear
reduced with time which advocates early diagnostic test-
ing, but the clinical possibility of loss of sensitisation is
intriguing. The finding that vancomycin-specific T cells
can be artificially expanded from individuals without clini-
cal reactivity, suggests that both immune predisposition
and potentially adaptive regulation may be important in
development of hypersensitivity responses to vancomycin.
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